Compare Abeona Therapeutics Inc (ABEO) vs Teradyne, Inc. (TER) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Teradyne, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Teradyne, Inc. trades at $343.58 (market cap $53.71B). The key difference: Teradyne, Inc. is far larger — about 143.9× Abeona Therapeutics Inc's market cap, and Teradyne, Inc. pays a 0.15% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | TER | |
|---|---|---|
Market Cap | $373.32M | $53.71B |
Sector | Health | Technology |
52-Week High | $7.23 | $483.84 |
52-Week Low | $4.17 | $90.15 |
Enterprise Value | $228.22M | $53.55B |
Dividend Yield | — | 0.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Teradyne (TER) trades at $343.11, down 7.04% amid a semiconductor sector sell-off, yet maintains strong fundamentals with 22.55% net margins and consistent earnings beats. The stock shows bearish technical signals but benefits from robust AI-driven demand, with 64.5% analyst buy ratings and a $453.60 consensus target suggesting 32% upside. Recent dividend declaration and strong cash flow generation support long-term stability despite near-term volatility.
Outlook remains positive given Teradyne's leadership in semiconductor testing and robotics, with AI infrastructure spending driving growth. Risks include sector cyclicality and premium valuations (P/E 70.4), but earnings momentum and institutional support provide cushion. The stock presents a compelling opportunity for investors seeking AI infrastructure exposure with proven execution capabilities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
